SHAREHOLDER ALERT: Rigrodsky Law, P.A. Announces Investigation of ChemoCentryx, Inc

Wilmington, Delaware--(Newsfile Corp. - February 4, 2022) - Rigrodsky Law, P.A. is investigating potential claims against the officers and directors of ChemoCentryx, Inc. ("ChemoCentryx") (NASDAQ: CCXI) on behalf of stockholders.

A class action complaint has been filed against ChemoCentryx. The complaint alleges that, between November 26, 2019 and May 6, 2021, defendants misrepresented and/or failed to disclose to investors that: (i) the study design of ChemoCentryx's Phase III ADVOCATE trial presented issues about the interpretability of the trial data to define a clinically meaningful benefit of the drug candidate avacopan and its role in the management of ANCA-associated vasculitis; (ii) the data from the Phase III ADVOCATE trial raised serious safety concerns for avacopan; (iii) these issues presented a substantial concern regarding the viability of ChemoCentryx's new drug application for avacopan for the treatment of ANCA-associated vasculitis; and (iv) as a result, defendants' public statements were materially false and misleading.

To learn more about this investigation and your rights, visit: https://www.rl-legal.com/cases-chemocentryx-inc.

You may also contact Seth D. Rigrodsky or Gina M. Serra cost and obligation free at (888) 969-4242 or info@rl-legal.com.

Rigrodsky Law, P.A., with offices in Delaware and New York, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in securities fraud and corporate class actions nationwide.

Attorney advertising. Prior results do not guarantee a similar outcome.

Rigrodsky Law, P.A.
Seth D. Rigrodsky
Gina M. Serra
(888) 969-4242 (Toll Free)
(302) 295-5310
Fax: (302) 654-7530
info@rl-legal.com
https://rl-legal.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/112800